Amneal Pharmaceuticals, Inc. AMRX Government label — Net revenue
Other product segments
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by Amneal Pharmaceuticals, Inc. in its filing.
Tagged under the XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.
The official record: Amneal Pharmaceuticals, Inc.’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →
Ask your AI about Amneal Pharmaceuticals, Inc.'s government label — net revenue.
Connect your AI assistant and compare segments, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Amneal Pharmaceuticals, Inc.'s government label — net revenue?
- Amneal Pharmaceuticals, Inc. (AMRX) reported government label — net revenue of $59.95M in Q1 2026.
- How has Amneal Pharmaceuticals, Inc.'s government label — net revenue changed year-over-year?
- Amneal Pharmaceuticals, Inc.'s government label — net revenue increased by 19.6% year-over-year, from $50.14M to $59.95M.
- What is the long-term trend for Amneal Pharmaceuticals, Inc.'s government label — net revenue?
- Over 4 years (2021 to 2025), Amneal Pharmaceuticals, Inc.'s government label — net revenue has grown at a 22.9% compound annual growth rate (CAGR), from $118.38M to $270.11M.
- What does government label — net revenue mean?
- This metric represents the total net revenue generated from the sale of pharmaceutical products specifically categorized under government-labeled or government-contracted programs. It reflects the company's ability to secure and fulfill supply agreements with public sector entities, which often serve as a stable, high-volume revenue stream. Monitoring this figure helps investors assess the company's exposure to public healthcare procurement and the competitive positioning of its portfolio within government-regulated markets.